Emerging Psychedelic Treatments: Opportunities and Challenges

CPD

Handouts

Speaker

Michael Mithoefer, MD Related seminars and products

---

Michael Mithoefer, MD, is clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

 

Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, University of South Carolina, Lykos Therapeutics and has ownership interest in Awakn Life Sciences. He is a sub-investigator and therapist at Zen Therapeutics and a consultant with MAPS. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.

Rick Doblin, PhD Related seminars and products

---

Rick Doblin, PhD, is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and dog.

 

Speaker Disclosures:
Financial: Richard Doblin has an employment relationship with Multidisciplinary Association for Psychedelic Studies, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Richard Doblin serve on the Board of Lykos Therapuetics.

Objectives

1. Appraise the rationale for researching MDMA as an adjunct to psychotherapy.
2. Analyze the results of Phase 2 and a recent Phase 3 Clinical Trial of MDMA-assisted Psychotherapy for PTSD.
3. Catalogue the major indications for which psilocybin has been studied.
4. Analyze the therapeutic method used in trials of MDMA-assisted psychotherapy for PTSD.
5. Quantify 2 physiological effects of MDMA that relate to medical contraindications.

Outline

• Background and effects of MDMA
  • Case reports of clinical use before MDMA was placed in schedule 1
  • Neurochemistry and physiological effects
     
• Results of clinical trials of MDMA-assisted psychotherapy
  • Timeline of research in past 20 years
  • Results of Phase 2 and Phase 3 clinical trials
     
• Psilocybin research
  • Brief review of indications studied in psilocybin clinical trials
  • Similarities and differences between therapeutic approaches in studies of psilocybin and studies of MDMA-assisted psychotherapy.
     
• The therapeutic method used in MDMA trials
  • The therapy Manual
  • Adherence criteria
  • Clinical vignettes from Clinical Trials illustrated with quotes and video clips
     
• The likely future roles of psychedelics in psychiatry and psychological

Target Audience

• Psychologists
• Physicians
• Addiction Counselors
• Counselors
• Social Workers
• Marriage & Family Therapists
• Art Therapists
• Nurses
• Other Behavioral Health Professionals

Reviews